Pfizer says the FDA has approved its migraine nasal spray Zavzpret

Pfizer said Friday that the Food and Drug Administration has approved a new nasal spray to treat migraines.

Zavzpret, a branded formulation of the generic drug zavegepant, is the "first and only" calcitonin gene-related peptide receptor antagonist nasal spray for preventing and treating migraines with or without an aura, or sensory disturbances such as flashes of light that can accompany a migraine, the drugmaker said. 

Zavzpret began working to treat migraine symptoms in as little as 30 minutes and provided some relief for up to 48 hours after the last administered dose, Pfizer said, citing a March study published in The Lancet. A 10mg dose of the drug proved more effective than a placebo at relieving pain and other migraine symptoms, the study found.